SG11202111986SA - Crystal polymorphism of pi3k inhibitor and method for preparing same - Google Patents
Crystal polymorphism of pi3k inhibitor and method for preparing sameInfo
- Publication number
- SG11202111986SA SG11202111986SA SG11202111986SA SG11202111986SA SG11202111986SA SG 11202111986S A SG11202111986S A SG 11202111986SA SG 11202111986S A SG11202111986S A SG 11202111986SA SG 11202111986S A SG11202111986S A SG 11202111986SA SG 11202111986S A SG11202111986S A SG 11202111986SA
- Authority
- SG
- Singapore
- Prior art keywords
- pi3k inhibitor
- preparing same
- crystal polymorphism
- polymorphism
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190054506A KR20200129704A (en) | 2019-05-09 | 2019-05-09 | Crystal Polymorphism of PI3K Inhibitor and Method for Producing the Same |
| PCT/IB2020/054366 WO2020225783A1 (en) | 2019-05-09 | 2020-05-08 | Crystal polymorphism of pi3k inhibitor and method for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111986SA true SG11202111986SA (en) | 2021-11-29 |
Family
ID=73051143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111986SA SG11202111986SA (en) | 2019-05-09 | 2020-05-08 | Crystal polymorphism of pi3k inhibitor and method for preparing same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220204502A1 (en) |
| EP (1) | EP3967692A1 (en) |
| JP (1) | JP2022532194A (en) |
| KR (2) | KR20200129704A (en) |
| CN (1) | CN114051498A (en) |
| AU (1) | AU2020268975A1 (en) |
| BR (1) | BR112021022546A2 (en) |
| CA (1) | CA3136569A1 (en) |
| MX (1) | MX2021013648A (en) |
| SG (1) | SG11202111986SA (en) |
| WO (1) | WO2020225783A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ612909A (en) * | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| AR092501A1 (en) * | 2012-09-13 | 2015-04-22 | Sanofi Sa | CRYSTAL COMPOUNDS |
| CN105102000B (en) * | 2012-11-01 | 2021-10-22 | 无限药品公司 | Cancer therapy using PI3 kinase subtype modulators |
| WO2015160975A2 (en) * | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| KR101845931B1 (en) * | 2015-06-18 | 2018-04-05 | 한국화학연구원 | Heteroaryl derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases |
| WO2016204429A1 (en) | 2015-06-18 | 2016-12-22 | 한국화학연구원 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient |
| NZ740616A (en) * | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
-
2019
- 2019-05-09 KR KR1020190054506A patent/KR20200129704A/en unknown
-
2020
- 2020-05-08 EP EP20801783.0A patent/EP3967692A1/en not_active Withdrawn
- 2020-05-08 AU AU2020268975A patent/AU2020268975A1/en not_active Abandoned
- 2020-05-08 CA CA3136569A patent/CA3136569A1/en not_active Abandoned
- 2020-05-08 JP JP2021566937A patent/JP2022532194A/en not_active Withdrawn
- 2020-05-08 BR BR112021022546A patent/BR112021022546A2/en unknown
- 2020-05-08 MX MX2021013648A patent/MX2021013648A/en unknown
- 2020-05-08 SG SG11202111986SA patent/SG11202111986SA/en unknown
- 2020-05-08 KR KR1020217040286A patent/KR20210155806A/en not_active Application Discontinuation
- 2020-05-08 WO PCT/IB2020/054366 patent/WO2020225783A1/en unknown
- 2020-05-08 US US17/609,289 patent/US20220204502A1/en active Pending
- 2020-05-08 CN CN202080046151.4A patent/CN114051498A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021022546A2 (en) | 2021-12-28 |
| JP2022532194A (en) | 2022-07-13 |
| CA3136569A1 (en) | 2020-11-12 |
| CN114051498A (en) | 2022-02-15 |
| MX2021013648A (en) | 2022-01-06 |
| KR20200129704A (en) | 2020-11-18 |
| AU2020268975A1 (en) | 2021-11-25 |
| US20220204502A1 (en) | 2022-06-30 |
| EP3967692A1 (en) | 2022-03-16 |
| WO2020225783A1 (en) | 2020-11-12 |
| KR20210155806A (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277127A (en) | Use of pcsk9 inhibitor for reducing cardiovascular risk | |
| EP3405943A4 (en) | Method and apparatus for reducing myopiagenic effect of electronic displays | |
| EP3859571A4 (en) | Method and apparatus for allocating copyrights of works based on blockchain | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| EP3310316A4 (en) | Method and apparatus for extracorporeal support of premature fetus | |
| IL283592A (en) | Inhibitors of apol1 and methods of using same | |
| GB2559579B (en) | Method of and apparatus for additive layer manufacture | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| EP3712130A4 (en) | Method for synthesis of roxadustat and intermediate compounds thereof | |
| IL287973A (en) | Acss2 inhibitors and methods of use thereof | |
| EP3611171A4 (en) | Method for synthesis of eliglustat and intermediate compounds thereof | |
| SG11202106326PA (en) | System and method for modification of substrates | |
| IL287293A (en) | Rna editing inhibitors and methods of use | |
| IL276312A (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| EP3591102A4 (en) | Compound semiconductor and method for producing single crystal of compound semiconductor | |
| EP3521276A4 (en) | Crystal form and salt form of and preparation method for tyrosine kinase inhibitor | |
| PT3725786T (en) | Crystal form and salt form of tgf-bri inhibitor and preparation method therefor | |
| EP3766870A4 (en) | Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| PT3532470T (en) | Oxazole derivatives for use as irak inhibitors and method for their preparation | |
| EP3793552C0 (en) | Abhd12 inhibitors and methods of making and using same | |
| SG11202111986SA (en) | Crystal polymorphism of pi3k inhibitor and method for preparing same | |
| ZA202107810B (en) | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | |
| ZA202003581B (en) | Crystal form of urat1 inhibitor, and preparation method therefor |